Table 1.
Baseline characteristics
| Cohort 1 (N=21) |
Cohort 2 (N=8) |
Total (N=29) |
|
|---|---|---|---|
| Age | |||
| Median (range) | 63.0 (43.0–82.0) | 61.0 (49.0–81.0) | 62.0 (43.0–82.0) |
| Gender | |||
| Female | 12 (57.1%) | 2 (25.0%) | 14 (48.3%) |
| Male | 9 (42.9%) | 6 (75.0%) | 15 (51.7%) |
| Race | |||
| White | 21 (100.0%) | 8 (100.0%) | 29 (100.0%) |
| Ethnicity | |||
| Not Hispanic or Latino | 21 (100.0%) | 8 (100.0%) | 29 (100.0%) |
| Performance Score | |||
| 0 | 9 (42.9%) | 5 (62.5%) | 14 (48.3%) |
| 1 | 8 (38.1%) | 2 (25.0%) | 10 (34.5%) |
| 2 | 4 (19.0%) | 1 (12.5%) | 5 (17.2%) |
| Durie-Salmon Stage at On Study | |||
| Missing | 1 | 0 | 1 |
| IA | 4 (20.0%) | 0 (0.0%) | 4 (14.3%) |
| IIA | 5 (25.0%) | 4 (50.0%) | 9 (32.1%) |
| IIIA | 11 (55.0%) | 4 (50.0%) | 15 (53.6%) |
| Prior Transplant | |||
| Yes | 16 (76.2%) | 7 (87.5%) | 23 (79.3%) |
| No | 5 (23.8%) | 1 (12.5%) | 6 (20.7%) |
| Number of Previous Regimens | |||
| Median (range) | 6.0 (2.0–15.0) | 5.0 (4.0–9.0) | 5.0 (2.0–15.0) |
| 2 – 4 | 6 (28.6%) | 2 (25%) | 8 (27.5%) |
| 5 – 7 | 9 (42.8%) | 4 (50.0%) | 13 (44.8%) |
| 8+ | 6 (28.5%) | 2 (25.0%) | 8 (27.5%) |
| Months from Diagnosis to On Study | |||
| Median (range) | 82.1 (8.6–163.8) | 83.7 (7.0–119.7) | 82.1 (7.0–163.8) |
Cohort I: Single agent MV-NIS; Cohort II: Cyclophosphamide and MV-NIS